BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1305 related articles for article (PubMed ID: 30791979)

  • 1. miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
    Lai Y; Kacal M; Kanony M; Stukan I; Jatta K; Kis L; Norberg E; Vakifahmetoglu-Norberg H; Lewensohn R; Hydbring P; Ekman S
    Biochem Biophys Res Commun; 2019 Apr; 511(2):260-265. PubMed ID: 30791979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammation-related molecular signatures involved in the anticancer activities of brigatinib as well as the prognosis of EML4-ALK lung adenocarcinoma patient.
    Ge FJ; Dai XY; Qiu Y; Liu XN; Zeng CM; Xu XY; Chen YD; Zhu H; He QJ; Gai RH; Ma SL; Chen XQ; Yang B
    Acta Pharmacol Sin; 2024 Jun; 45(6):1252-1263. PubMed ID: 38360931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
    Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
    Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism.
    Xie B; Qiu Y; Zhou J; Du D; Ma H; Ji J; Zhu L; Zhang W
    Clin Transl Oncol; 2022 Nov; 24(11):2231-2240. PubMed ID: 35852680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
    Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
    Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.
    Peters S; Zimmermann S
    Curr Treat Options Oncol; 2018 May; 19(7):37. PubMed ID: 29808239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition.
    Kogita A; Togashi Y; Hayashi H; Sogabe S; Terashima M; De Velasco MA; Sakai K; Fujita Y; Tomida S; Takeyama Y; Okuno K; Nakagawa K; Nishio K
    Int J Oncol; 2014 Oct; 45(4):1430-6. PubMed ID: 25096400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ALK-rearrangement in non-small-cell lung cancer (NSCLC).
    Du X; Shao Y; Qin HF; Tai YH; Gao HJ
    Thorac Cancer; 2018 Apr; 9(4):423-430. PubMed ID: 29488330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC.
    Bokhari AA; Lai WY; Le AT; Gabre JL; Chuang TP; Fransson S; Bergman B; Djos A; Chen N; Martinsson T; Van den Eynden J; Doebele RC; Palmer RH; Hallberg B; Umapathy G
    Lung Cancer; 2022 Sep; 171():103-114. PubMed ID: 35933914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.
    Yamaguchi N; Lucena-Araujo AR; Nakayama S; de Figueiredo-Pontes LL; Gonzalez DA; Yasuda H; Kobayashi S; Costa DB
    Lung Cancer; 2014 Jan; 83(1):37-43. PubMed ID: 24199682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A Case of Non-small Cell Lung Cancer Treated with Three ALK Inhibitors 
and Chemotherapy].
    Wang J; Xu X; Sun Y; Li H
    Zhongguo Fei Ai Za Zhi; 2021 May; 24(5):372-376. PubMed ID: 34034462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
    Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
    Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.
    Katayama R; Khan TM; Benes C; Lifshits E; Ebi H; Rivera VM; Shakespeare WC; Iafrate AJ; Engelman JA; Shaw AT
    Proc Natl Acad Sci U S A; 2011 May; 108(18):7535-40. PubMed ID: 21502504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
    Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
    Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
    Toyokawa G; Seto T
    Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
    Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
    Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.
    Lin JJ; Zhu VW; Yoda S; Yeap BY; Schrock AB; Dagogo-Jack I; Jessop NA; Jiang GY; Le LP; Gowen K; Stephens PJ; Ross JS; Ali SM; Miller VA; Johnson ML; Lovly CM; Hata AN; Gainor JF; Iafrate AJ; Shaw AT; Ou SI
    J Clin Oncol; 2018 Apr; 36(12):1199-1206. PubMed ID: 29373100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anaplastic Lymphoma Kinase Fusion: A Review of Therapeutic Drugs and Treatment Strategies.
    Makimoto G; Ohashi K; Maeda Y; Kiura K
    Acta Med Okayama; 2020 Oct; 74(5):371-379. PubMed ID: 33106692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.
    Kimura H; Nakajima T; Takeuchi K; Soda M; Mano H; Iizasa T; Matsui Y; Yoshino M; Shingyoji M; Itakura M; Itami M; Ikebe D; Yokoi S; Kageyama H; Ohira M; Nakagawara A
    Lung Cancer; 2012 Jan; 75(1):66-72. PubMed ID: 21757253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 66.